Aducanumab was controversially approved by the FDA in June despite an advisory panel recommending against its approval

A new study published in the journal JAMA Neurology is reporting more than one in three patients trialing the recently approved Alzheimer’s drug aducanumab experienced brain swelling side effects. The data is the first from the controversial drug’s Phase 3 trials to be peer-reviewed and published.

Continue Reading

Category: Medical, Science

Tags: , , ,